Biomarkers in the prediction of contrast media induced nephropathy - the BITCOIN study

Felix S Seibert, Anja Heringhaus, Nikolaos Pagonas, Henrik Rudolf, Benjamin Rohn, Frederic Bauer, Nina Timmesfeld, Hans-Joachim Trappe, Nina Babel, Timm H Westhoff, Felix S Seibert, Anja Heringhaus, Nikolaos Pagonas, Henrik Rudolf, Benjamin Rohn, Frederic Bauer, Nina Timmesfeld, Hans-Joachim Trappe, Nina Babel, Timm H Westhoff

Abstract

Background: Subjects with chronic kidney disease are at increased risk for contrast-induced acute kidney injury (CI-AKI). Risk stratification is traditionally based on glomerular filtration rate (GFR) and proteinuria. The present trial examines, whether tubular and inflammatory biomarkers are able to identify subjects at increased risk as well.

Methods: We performed a prospective study in 490 patients undergoing coronary angiography. An increase of serum creatinine concentration ≥ 0.3 mg/dl from baseline to day 2-3 was defined as primary endpoint (CI-AKI). Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and calprotectin were assessed < 24h before coronary angiography. Prognostic accuracy was assessed by receiver operating characteristics (ROC) calculations.

Results: 30 (6.1%) patients suffered from CI-AKI (27 AKIN stage I, 3 AKIN stage II, 0 AKIN stage III). Those subjects who developed CI-AKI had 3.1 fold higher baseline urinary NGAL/creatinine ratios than those without CI-AKI (60.8 [IQR 18.7-93.1] μg/mg vs. 19.9 [IQR 12.3-38.9] μg/mg, p = 0.001). In those subjects without clinically overt CKD (eGFR > 60 ml/min, urinary albumin creatinine ratio <30 mg/g), the NGAL/creatinine ratio was 2.6 higher in CI-AKI vs. no CI-AKI (47.8 [IQR 11.8-75.3] vs. 18.6 [IQR 11.7-36.3] μg/mg). No significant differences were obtained for KIM-1 and calprotectin (p>0.05 each). ROC analyses revealed an area under the curve (AUC) of 0.68 (95% CI 0.60-0.81) for NGAL/creatinine. An NGAL/creatinine ratio < 56.4 μg/mg has a negative predictive value of 96.5%.

Conclusions: The present study is the largest investigation on the use of urinary biomarkers for CI-AKI risk stratification so far. It shows that NGAL provides prognostic information beyond the glomerular biomarkers eGFR and proteinuria.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute kidney injury (CI-AKI) after coronary angiography for (A) neutrophil gelatinase-associated lipocalin (NGAL), (B) kidney injury molecule-1 (KIM-1), and (C) calprotectin. Data are presented as scatter plots (logarithmic Y-axis, medians and interquartile ranges are indicated by horizontal lines). Significant differences were ***p

Fig 2. Individual urinary biomarker-creatinine ratios of…

Fig 2. Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute…

Fig 2. Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute kidney injury (CI-AKI) after coronary angiography in the subgroup of patients without clinically overt kidney disease (eGFR > 60 ml, ACR > 30 mg/g creatinine; left column).
Analyses are presented for (A) neutrophil gelatinase-associated lipocalin (NGAL), (B) kidney injury molecule-1 (KIM-1), and (C) calprotectin. Data are presented as scatter plots (logarithmic Y-axis, medians and interquartile ranges are indicated by horizontal lines). Significant differences were ***p

Fig 3

Accuracy of biomarker-creatinine ratios of…

Fig 3

Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney…

Fig 3
Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney injury molecule-1 (KIM-1, red) and calprotectin (green) in the prediction of contrast media induced acute kidney injury (CI-AKI) after coronary angiography in receiver operating characteristic (ROC) analysis. The predictive accuracy for CI-AKI in the present study population following the models of Ghani et al. (blue) and Inohara et al. (green) is displayed in (B). ROC curves adding NGAL/creatinine as predictor into the model are displayed in red and black, respectively. AUC–area under the curve. Diagonal scattered lines indicate prediction of CI-AKI by chance.
Similar articles
Cited by
References
    1. Christiansen C. X-ray contrast media—an overview. Toxicology. 2005;209(2):185–7. Epub 2005/03/16. 10.1016/j.tox.2004.12.020 . - DOI - PubMed
    1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–70. Epub 2005/09/24. 10.1681/ASN.2004090740 . - DOI - PubMed
    1. Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013;4(6):811–20. Epub 2013/10/05. 10.1007/s13244-013-0291-3 - DOI - PMC - PubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31 Epub 2007/03/03. 10.1186/cc5713 - DOI - PMC - PubMed
Show all 32 references
Publication types
MeSH terms
Grant support
The study was funded by the German Research Foundation (Research Unit FOR1368; receiver TW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig 2. Individual urinary biomarker-creatinine ratios of…
Fig 2. Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute kidney injury (CI-AKI) after coronary angiography in the subgroup of patients without clinically overt kidney disease (eGFR > 60 ml, ACR > 30 mg/g creatinine; left column).
Analyses are presented for (A) neutrophil gelatinase-associated lipocalin (NGAL), (B) kidney injury molecule-1 (KIM-1), and (C) calprotectin. Data are presented as scatter plots (logarithmic Y-axis, medians and interquartile ranges are indicated by horizontal lines). Significant differences were ***p

Fig 3

Accuracy of biomarker-creatinine ratios of…

Fig 3

Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney…

Fig 3
Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney injury molecule-1 (KIM-1, red) and calprotectin (green) in the prediction of contrast media induced acute kidney injury (CI-AKI) after coronary angiography in receiver operating characteristic (ROC) analysis. The predictive accuracy for CI-AKI in the present study population following the models of Ghani et al. (blue) and Inohara et al. (green) is displayed in (B). ROC curves adding NGAL/creatinine as predictor into the model are displayed in red and black, respectively. AUC–area under the curve. Diagonal scattered lines indicate prediction of CI-AKI by chance.
Fig 3
Fig 3
Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney injury molecule-1 (KIM-1, red) and calprotectin (green) in the prediction of contrast media induced acute kidney injury (CI-AKI) after coronary angiography in receiver operating characteristic (ROC) analysis. The predictive accuracy for CI-AKI in the present study population following the models of Ghani et al. (blue) and Inohara et al. (green) is displayed in (B). ROC curves adding NGAL/creatinine as predictor into the model are displayed in red and black, respectively. AUC–area under the curve. Diagonal scattered lines indicate prediction of CI-AKI by chance.

References

    1. Christiansen C. X-ray contrast media—an overview. Toxicology. 2005;209(2):185–7. Epub 2005/03/16. 10.1016/j.tox.2004.12.020 .
    1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–70. Epub 2005/09/24. 10.1681/ASN.2004090740 .
    1. Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013;4(6):811–20. Epub 2013/10/05. 10.1007/s13244-013-0291-3
    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31 Epub 2007/03/03. 10.1186/cc5713
    1. Heller F, Frischmann S, Grunbaum M, Zidek W, Westhoff TH. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol. 2011;6(10):2347–55. Epub 2011/09/03. 10.2215/CJN.02490311
    1. Seibert FS, Sitz M, Passfall J, Haesner M, Laschinski P, Buhl M, et al. Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease. Kidney Blood Press Res. 2018;43(4):1255–62. Epub 2018/08/06. 10.1159/000492407 .
    1. Westhoff JH, Fichtner A, Waldherr S, Pagonas N, Seibert FS, Babel N, et al. Urinary biomarkers for the differentiation of prerenal and intrinsic pediatric acute kidney injury. Pediatr Nephrol. 2016;31(12):2353–63. Epub 2016/06/12. 10.1007/s00467-016-3418-1 .
    1. Seibert FS, Pagonas N, Arndt R, Heller F, Dragun D, Persson P, et al. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiol (Oxf). 2013;207(4):700–8. 10.1111/apha.12064 .
    1. Seibert FS, Rosenberger C, Mathia S, Arndt R, Arns W, Andrea H, et al. Urinary Calprotectin Differentiates Between Prerenal and Intrinsic Acute Renal Allograft Failure. Transplantation. 2017;101(2):387–94. 10.1097/TP.0000000000001124 .
    1. Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm Allergy Drug Targets. 2011;10(4):260–71. Epub 2011/05/05. 10.2174/187152811796117735 .
    1. Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, et al. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016;27(7):2109–21. Epub 2015/11/06. 10.1681/ASN.2015030292
    1. Waikar SS, Sabbisetti V, Arnlov J, Carlsson AC, Coresh J, Feldman HI, et al. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant. 2016;31(9):1460–70. Epub 2016/06/09. 10.1093/ndt/gfw203
    1. Tepel M, Borst C, Bistrup C, Marcussen N, Pagonas N, Seibert FS, et al. Urinary calprotectin and posttransplant renal allograft injury. PLoS One. 2014;9(11):e113006 10.1371/journal.pone.0113006
    1. Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, et al. Dynamics of Urinary Calprotectin after Renal Ischaemia. PLoS One. 2016;11(1):e0146395 10.1371/journal.pone.0146395
    1. Westhoff JH, Seibert FS, Waldherr S, Bauer F, Tonshoff B, Fichtner A, et al. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury. Eur J Pediatr. 2017;176(6):745–55. 10.1007/s00431-017-2907-y .
    1. Neuhaus J, Bauer F, Fitzner C, Hilgers RD, Seibert F, Babel N, et al. Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy. Kidney Blood Press Res. 2018;43(5):1563–72. Epub 2018/10/23. 10.1159/000494442 .
    1. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scandinavian journal of clinical and laboratory investigation. 2010;70(5):374–82. Epub 2010/06/01. 10.3109/00365513.2010.486868 .
    1. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45. Epub 1988/09/01. .
    1. Inohara T, Kohsaka S, Abe T, Miyata H, Numasawa Y, Ueda I, et al. Development and validation of a pre-percutaneous coronary intervention risk model of contrast-induced acute kidney injury with an integer scoring system. Am J Cardiol. 2015;115(12):1636–42. Epub 2015/04/22. 10.1016/j.amjcard.2015.03.004 .
    1. Ghani AA, Tohamy KY. Risk score for contrast induced nephropathy following percutaneous coronary intervention. Saudi J Kidney Dis Transpl. 2009;20(2):240–5. Epub 2009/02/25. .
    1. Liebetrau C, Gaede L, Doerr O, Blumenstein J, Rixe J, Teichert O, et al. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014;74(2):81–8. Epub 2013/12/07. 10.3109/00365513.2013.860615 .
    1. Luo Q, Zhou F, Dong H, Wu L, Chai L, Lan K, et al. Implication of combined urinary biomarkers in early diagnosis of acute kidney injury following percutaneous coronary intervention. Clin Nephrol. 2013;79(2):85–92. Epub 2012/11/01. 10.5414/CN106852 .
    1. Cecchi E, Avveduto G, D'Alfonso MG, Terreni A, Gelera E, Caldini A, et al. Cystatin C, but not urinary or serum NGAL, may be associated with contrast induced nephropathy after percutaneous coronary invasive procedures: A single center experience on a limited number of patients. Acta Med Acad. 2017;46(1):34–43. Epub 2017/06/14. 10.5644/ama2006-124.184 .
    1. Chen JJ, Fan PC, Kou G, Chang SW, Chen YT, Lee CC, et al. Meta-Analysis: Urinary Calprotectin for Discrimination of Intrinsic and Prerenal Acute Kidney Injury. J Clin Med. 2019;8(1). 10.3390/jcm8010074
    1. Tan X, Zheng X, Huang Z, Lin J, Xie C, Lin Y. Involvement of S100A8/A9-TLR4-NLRP3 Inflammasome Pathway in Contrast-Induced Acute Kidney Injury. Cell Physiol Biochem. 2017;43(1):209–22. 10.1159/000480340 .
    1. Jabara R, Gadesam RR, Pendyala LK, Knopf WD, Chronos N, Chen JP, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009;103(12):1657–62. 10.1016/j.amjcard.2009.02.039 .
    1. Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22. 10.1016/S0140-6736(17)30057-0 .
    1. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603–14. Epub 2017/11/14. 10.1056/NEJMoa1710933 .
    1. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International. 2012; Volume 2(1).
    1. Serif L, Chalikias G, Didagelos M, Stakos D, Kikas P, Thomaidis A, et al. Application of 17 Contrast-Induced Acute Kidney Injury Risk Prediction Models. Cardiorenal Med. 2020:1–13. Epub 2020/04/15. 10.1159/000506379 .
    1. Allen DW, Ma B, Leung KC, Graham MM, Pannu N, Traboulsi M, et al. Risk Prediction Models for Contrast-Induced Acute Kidney Injury Accompanying Cardiac Catheterization: Systematic Review and Meta-analysis. Can J Cardiol. 2017;33(6):724–36. Epub 2017/05/27. 10.1016/j.cjca.2017.01.018 .

Source: PubMed

3
구독하다